Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Turn Therapeutics Inc.NASDAQ: TTRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA of -$956.52K in Q1 FY2026
Q1 FY2026 EBITDA was -$956.52K. Trailing-twelve-month EBITDA was -$3.79M.
Context
- EBITDA grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -82.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$956.52K-426.2% QoQ
- Last fiscal yearDec 2025
- -$3.14M-82.5% YoY
- LTMMar 2026
- -$3.79M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +100.0% | — |
| 1 year | -82.5% | +100.0% | +182.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (3.14M) USD
- Year-over-year change
- -82.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.14M) | -82.5% |
| FY2024 | 2024-12-31 | (1.72M) | +23.5% |
| FY2023 | 2023-12-31 | (2.25M) | — |
EBITDA vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 EBITDA of -$3.79M is the 2nd highest of the 9 companies compared; the peer median is -$25.97M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.79M | — | — | — |
| LTM Apr 2026 | -$10.1M | +17.4% | — | — | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
| LTM Mar 2026 | -$21.76M | -35.5% | — | — | |
| LTM Mar 2026 | -$30.19M | -68.1% | — | — | |
| LTM Mar 2026 | -$53.92M | -39.7% | — | — | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$104.73M | -226.0% | — | 874.0% |
| Peer median (excluding TTRX) | -$25.97M | -9.0% | — | 427.9% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 7.5K | 245.96K | 265.57K |
| Selling, General & Admin | 2.3M | 1.55M | 5.59M |
| Operating Expenses | 2.31M | 1.8M | 5.86M |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| EBITDA | (2.25M) | (1.72M) | (3.14M) |
| EBITDA Margin | — | — | — |
| Operating Income | (2.31M) | (1.8M) | (5.86M) |
| Operating Margin | — | — | — |
| Interest Income | 15.88K | 28.71K | 29.58K |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 15.88K | 28.71K | 2.66M |
| Income Before Tax | (2.29M) | (1.77M) | (3.19M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.17) | (0.13) | (0.23) |
| EPS (Diluted) | (0.17) | (0.13) | (0.23) |
| Weighted Avg Shares | 13.25M | 13.42M | 13.74M |
| Weighted Avg Shares (Diluted) | 13.25M | 13.42M | 13.74M |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.